Biological roles of SLC16A1-AS1 lncRNA and its clinical impacts in tumors

• Published in: Cancer cell international Vol. 24; no. 1; pp. 122 - 12
• Main Authors: Liao, Bing, Wang, Jialing, Yuan, Yalin, Luo, Hongliang, Ouyang, Xi
• Format: Journal Article
• Language: English
• Published: England BioMed Central 30.03.2024; BMC
• Subjects: Apoptosis; Biomarkers; Brain cancer; Cancer biomarker; Cancer therapies; Cell cycle; Cell growth; CRISPR; Disease; Ferroptosis; Gene expression; Glioma; Human tumor; Kidney cancer; Liver cancer; Medical prognosis; Medical research; Metabolism; MicroRNAs; Review; Roles; SLC16A1-AS1; Squamous cell carcinoma; Therapeutic targets; Tumor suppressor genes; Tumorigenesis; Tumors; Cancer biomarker; SLC16A1-AS1; Tumorigenesis; Human tumor
• ISSN: 1475-2867; 1475-2867
• DOI: 10.1186/s12935-024-03285-6

Recent studies have increasingly highlighted the aberrant expression of SLC16A1-AS1 in a variety of tumor types, where it functions as either an oncogene or a tumor suppressor in the pathogenesis of different cancers. The expression levels of SLC16A1-AS1 have been found to significantly correlate with clinical features and the prognosis of cancer patients. Furthermore, SLC16A1-AS1 modulates a range of cellular functions, including proliferation, migration, and invasion, through its interactions with diverse molecules and signaling pathways. This review examines the latest evidence regarding the role of SLC16A1-AS1 in the progression of various tumors and explores its potential clinical applications as a novel prognostic and diagnostic biomarker. Our comprehensive review aims to deepen the understanding of SLC16A1-AS1’s multifaceted role in oncology, underscoring its potential as a significant biomarker and therapeutic target.